Lung Cancer Study

Have You Or Has Someone In Your Family Been Diagnosed With Lung Cancer?

Did you know that 1 in 4 people diagnosed with lung cancer have the KRAS-variant, an inherited gene mutation that provides powerful, life-saving information about how an individual will respond to specific cancer treatments?

If you or a family member has had lung cancer, you are eligible to join a study to explore the relationship between genes and cancer treatment. If you would like to join a study, please complete the eligibility survey.

Take The Eligibility Survey

Stay up-to-date on the latest stories, events, news & research through our e-newsletter.

What we know about the KRAS-variant:

  • Found in 6-10% of the population
  • Predicts sensitivity and resistance to several standard-of-care cancer treatments/therapies
  • Associated primarily with post-menopausal cancer in women, enabling the opportunity for cancer prevention through informed decision making about oophorectomy (ovarian removal) at menopause
  • Explains the genetic cause of cancer for over 50% of Hereditary Breast and Ovarian Cancer (HBOC) families with no other known genetic markers
  • Cancer risk may be influenced by estrogen loss


We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study.  If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.

Take the Survey

MiraKind’s pipeline of planned and ongoing research studies are designed to protect the health of individuals with the KRAS-variant and to help answer the most pressing questions about cancer. Research questions include:

  • What are the best cancer management strategies for KRAS-variant cancer patients
  • What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence cancer risk for individuals with the KRAS-variant?
  • How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
  • How can we prevent cancers associated with the KRAS-variant for family members who are positive but have never been diagnosed with cancer?

If you want to know more about the research, please see our study overview page, and if you have questions please see our FAQ section.

MiraKind / 11600 Wilshire Boulevard, Los Angeles, CA 90025 /

arrow up to top